Ülke: İsrail
Dil: İngilizce
Kaynak: Ministry of Health
TOBRAMYCIN
NOVARTIS ISRAEL LTD
J01GB01
EYE DROPS
TOBRAMYCIN 0.3 %
OCULAR
Required
ALCON CUSI S.A., SPAIN
TOBRAMYCIN
TOBRAMYCIN
Antibiotic for the treatment of superficial eye infections caused by bacteria sensitive to Tobramycin.
2012-05-31
PATIENT PACKAGE INSERT IN ACCORDANCE WITH THE PHARMACISTS’ REGULATIONS )PREPARATIONS( – 1986 The medicine is dispensed with a doctor’s prescription only ESCITALOPRAM TEVA 10 MG TABLETS The active ingredient and its quantity: Each tablet contains: Escitalopram )as oxalate( 10 mg ESCITALOPRAM TEVA 20 MG TABLETS The active ingredient and its quantity: Each tablet contains: Escitalopram )as oxalate( 20 mg For information on the inactive ingredients, see section 2 – “Important information about some of the ingredients of the medicine” and section 6 – “Further Information”. READ THE LEAFLET CAREFULLY IN ITS ENTIRETY BEFORE USING THE MEDICINE. This leaflet contains concise information about the medicine. If you have further questions, refer to the doctor or pharmacist. This medicine has been prescribed for you. Do not pass it on to others. It may harm them even if it seems to you that their medical condition is similar. This medicine is not usually intended for use in children and adolescents under the age of 18. Antidepressants and anti-anxiety medicines increase the risk of suicidal behavior and thoughts in children, adolescents and young adults up to the age of 25. Upon commencement of treatment with the medicine, patients of all ages, and their relatives, must monitor behavioral changes, such as: worsening of depression, suicidal thoughts, aggressiveness and the like. If such changes occur, refer to a doctor immediately. 1. WHAT IS THE MEDICINE INTENDED FOR? Escitalopram Teva is an antidepressant from the selective serotonin reuptake inhibitors )SSRI( group. Medicines belonging to this group act on the serotonin system in the brain by increasing serotonin levels. Disruptions in the serotonin system are considered important factors in development of depression and diseases associated with depression. Escitalopram Teva is used to treat the following conditions: depression panic disorders generalized anxiety social anxiety obsessive-compulsive disorder A few weeks may pass until you start to feel bett Belgenin tamamını okuyun
TOB 2X API JAN22 V2 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT TOBREX 2X 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each mL of Tobrex 2X eye drops contains the active ingredient tobramycin 3 mg in 1 mL. Excipient with known effect Preservative: Benzododecinium bromide (BDAB) For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Eye drops. 4. CLINICAL PARTICULARS 4.1. THERAPEUTIC INDICATIONS Antibiotic for the treatment of superficial eye infections caused by bacteria sensitive to Tobramycin. 4.2. DOSE AND METHOD OF ADMINISTRATION The dose is one drop of TOBREX 2X eye drops into the conjunctival sac two times daily (morning and evening) for 7±1 days. If severe disease: on the first day, four instillations while awake. Thereafter instill one drop in each eye twice a day, while awake, until completion of the 7±1 days-total treatment period. To prevent contamination of the dropper tip and solution, care must be taken not to touch the eyelids, surrounding areas, or other surfaces with the dropper tip of the bottle. Keep the bottle tightly closed when not in use. After cap is removed, if the tamper evident snap collar is loose, remove before using the product. In case of concomitant therapy with other topical ocular medicines, an interval of 5-10 minutes should be allowed between successive applications. _Use in elderly _ No dosage adjustment in elderly patients is necessary. _Paediatric Population _ TOBREX 2X eye drops may be used in children 1 year of age and older at the same dose as in adults. The safety and efficacy in children younger than 1 year of age have not been established, and no data are available. TOB 2X API JAN22 V2 _ _ _Use in hepatic and renal impairment _ Ocular application of tobramycin gives very little systemic exposure. In case of concomitantly administered systemic treatment with aminoglycoside antibiotics, care should be taken to monitor the total serum concentration in order to ensure that an appropriate therapeutic level is maintained. 4.3. CONTR Belgenin tamamını okuyun